Videos

Experts in breast oncology review 3 clinical cases of HER2+ breast cancer and discuss individualized treatment approaches for each patient.

Michael Wang, MD, discusses the role of BTK inhibitors as treatment of patients with mantle cell lymphoma ahead of his presentation at the 2020 SOHO Annual Meeting.

Ulka Vaishampayan, MD, discusses the use of tivozanib as treatment of patients with advanced renal cell carcinoma, based on supportive data in the TIVO-3 clinical trial.

John M. Burke, MD, discusses treatment with rituximab versus obinutuzumab in patients with advanced stage follicular lymphoma with high tumor burden.

Lyudmila Bazhenova, MD, presents the case of a 58-year-old woman with ALK+ non–small cell lung cancer.

Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.

Michael J. Morris, MD, discusses the safety and clinical activity of atezolizumab plus radium-223 dichloride in patients with second-line metastatic castration-resistant prostate cancer.

Jennifer Woyach, MD, discusses the rationale and efficacy for the phase 1/2 trial of acalabrutinib in patients with chronic lymphocytic leukemia.

Edward B. Garon, MD, discusses an exciting new agent, or class of agents, that are under evaluation as treatment of patients with non-small cell lung cancer.

Jerry L. Spivak, MD, discusses treating patients with polycythemia vera, which is a type of myeloproliferative neoplasm that can often derive from essential thrombocythemia, particularly among women.